{
  "symbol": "PCRX",
  "company": "Pacira BioSciences, Inc.",
  "generated_at": "2026-06-24T07:36:51.602Z",
  "event_count": 3,
  "events": [
    {
      "type": "pipeline_event",
      "ts": "2026-06-13T01:39:04.359Z",
      "stage": "analyst",
      "outcome": "skip",
      "reason": "Fails the concentration anti-signal gate (79% of sales routed through three wholesalers) and scores poorly across all rubric categories due to zero smart-money conviction, deteriorating earnings surprise history, thin margins, and lack of a near-term asymmetric catalyst.",
      "trigger": "[insider_cluster_universe] 9 Form 4 filings in last 14 days · at least one open-market P/S trade verified",
      "source": "idle_hunter"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-06-13T01:39:04.344Z",
      "skip": true,
      "reason": "Fails the concentration anti-signal gate (79% of sales routed through three wholesalers) and scores poorly across all rubric categories due to zero smart-money conviction, deteriorating earnings surprise history, thin margins, and lack of a near-term asymmetric catalyst.",
      "score": 4,
      "breakdown": {
        "smart_money": 0,
        "options_flow": 0,
        "catalyst": 0,
        "mispricing": 2,
        "quality": 0,
        "technical": 2
      },
      "debug_path": "drafts/2026-06-13-PCRX.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-13T01:38:27.652Z",
      "summary": "Pacira is a specialty pharma focused on non-opioid pain management with three commercial products: EXPAREL (80% of revenue), ZILRETTA (OA knee), and iovera° (cryoanalgesia device). The investigation trigger cited insider cluster activity but Form 4 filings for the past several weeks returned zero results — a discrepancy worth flagging. The stock trades near its 52-week range at forward P/E ~6.3x, which is cheap relative to peers but explained by thin margins (ROIC low), heavy SG&A spend, and revenue concentration in three products from three wholesalers (~79%). An activist contest from DOMA Perpetual Capital Management (7.5% holder) at the June 2026 annual meeting produced mixed outcomes — management's board nominees won cleanly, but Say-on-Pay failed narrowly and the Stock Incentive Plan was rejected by stockholders, signaling governance friction without triggering a board change.",
      "verdict": "range_bound_or_income",
      "confidence": 4,
      "tool_calls": 15,
      "walltime_min": 15,
      "debug_path": "dossiers/2026-06-13-PCRX.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "PCRX",
    "call": "HOLD",
    "confidence": 3,
    "score": 3,
    "factors": {
      "above_200dma": "+2",
      "below_50dma": "-1",
      "momentum_flat": "0 (-4.6%)",
      "rsi_neutral": "0 (54.7)",
      "macd_above_signal": "+1",
      "recent_macd_bullish_cross": "+1 (0d ago)",
      "from_high": "0 (-13.6%)"
    },
    "summary": "HOLD (score +3) · 12-1 mom -4.6% · RSI 54.7 · above_200_only · -13.6% from high",
    "last_close": 23.51,
    "one_month_ago_close": 23.48,
    "twelve_month_ago_close": 24.62,
    "twelve_one_momentum_pct": -4.63,
    "rsi_14": 54.7,
    "ma_stack": "above_200_only",
    "from_period_high_pct": -13.63,
    "period_high": 27.22,
    "price_targets": {
      "bear": 19.05,
      "fair": 25.6,
      "bull": 38,
      "bear_return_pct": -19,
      "fair_return_pct": 8.9,
      "bull_return_pct": 61.6,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 23,
        "target_mean": 29.66667,
        "target_high": 38,
        "analyst_count": 6
      }
    },
    "generated_at": "2026-06-24T07:36:51.598Z"
  }
}